scholarly journals Research of the epidemiology on cancer of the trachea, bronchi, lungs as important components in the development of effective directions for increasing the effectiveness of pharmaceutical support for cancer patients

Author(s):  
Yurii Pulnyi ◽  
Hanna Panfilova ◽  
Ellona Shelkova ◽  
Oleksandr Kabachnyi ◽  
Vitaly Chernukha

The aim: to conduct epidemiological studies on cancer of the trachea, bronchi, lungs as important components in the development of effective directions for increasing the effectiveness of pharmaceutical support for cancer patients in Ukraine. Materials and methods. The study used data from special literature, which presents the results of research on cancer in different countries of the world and data from the National Cancer Registry from 2014-2019 by indicators of morbidity and mortality of the population of Ukraine from cancer of the trachea, bronchi and lungs, including by gender. General theoretical (historical, analytical-comparative, systemic, graphic, logical, hypothetical-deductive) and applied (mathematical-statistical, epidemiological) research methods were used. Results. It was found that during 2014-2018 in terms of morbidity and mortality of the population from cancer of the trachea, bronchi and lungs in Ukraine, there was a positive dynamics of decline. So, in terms of incidence rates, which are standardized by WHO in 2018, the data decreased compared to 2014 by 8.4 %, and according to the “Ukrainian standard” – by 7.0 %. Mortality rates, which were standardized by WHO, decreased in 2018 compared to 2014 by 12.1 %, and those presented according to the “Ukrainian standard” – by 11.1 %. It was proved that the average data on morbidity and mortality of male patients were 6.2 and 7.4 times higher than in the same data for female patients. The different nature of changes in morbidity and mortality rates of patients in accordance with their gender in the dynamics of years has been established. So, for the female cohort of patients, the incidence and mortality rate from cancer of the trachea, bronchi and lungs during 2014-2018 had a complex zigzag character of changes, and in 2019, compared with the data of 2014, they increased by 22.54 % and 23.6 %, respectively. In the male cohort of patients, we observed a positive trend towards a decrease in mortality during 2014-2019. So, in 2019, these indicators reached their minimum and were equal to 57.0 and 44.0 cases per 100 thousand population. According to the data of 2019, the incidence and mortality of men from cancer of the trachea, bronchi and lungs relative to the data of 2014 decreased by 21.4 % and 25.0 %, respectively. It looks encouraging that there was relatively little fluctuation during 2014-2019 epidemiological indicators, both in general for the entire population of patients and female patients. Conclusions. The established characteristics and trends in the formation of the onco-epidemiological profile of the country's population for trachea, bronchus and lung cancer in dynamics over the years necessitate further research, taking into account changes in the main demographic indicators development of society

2010 ◽  
Vol 138 (9) ◽  
pp. 1215-1226 ◽  
Author(s):  
C. L. FISCHER WALKER ◽  
R. E. BLACK

SUMMARYDiarrhoea is a leading cause of morbidity and mortality yet diarrhoea specific incidence and mortality rates for older children, adolescents, and adults have not been systematically calculated for many countries. We conducted a systematic literature review to generate regional incidence rates by age and to summarize diarrhoea specific mortality rates for regions of the world with inadequate vital registration data. Diarrhoea morbidity rates range from 29·9 episodes/100 person-years for adults in the South East Asian region to 88·4 episodes/100 person-years in older children in the Eastern Mediterranean region and have remained unchanged in the last 30 years. Diarrhoea mortality rates decline as the child ages and remain relatively constant during adulthood. These data are critical for improving estimates worldwide and further highlight the need for improved diarrhoea specific morbidity and mortality data in these age groups.


2020 ◽  
Vol 23 (7) ◽  
pp. 434-444
Author(s):  
Sahar Eftekharzadeh ◽  
Narges Ebrahimi ◽  
Mehrnoosh Samaei ◽  
Farnam Mohebi ◽  
Bahram Mohajer ◽  
...  

Background: The present study aims to assess the incidence and mortality rates of gynecological cancers and their changes from 1990 to 2016 at national and subnational levels in Iran. Methods: Annual estimates of incidence and mortality for gynecological cancers from 1990 to 2016 at national and subnational levels were generated as part of a larger project entitled National and Subnational Burden of Diseases, Injuries, and Risk Factors (NASBOD). After the precise processing of data extracted from the Iran Cancer Registry, annual age-standardized incidence and mortality rates were calculated for each cancer, province, year and age group during the period of the study. Results: In 2016, gynecological cancers constituted 8.0% of new cancer cases among women of all ages compared to 3.7% of new cases of cancer among women in 1990. The incidence rate of gynecological cancers has increased from 2.5 (0.9-5.6) per 100000 women in 1990 to 12.3 (9.3–15.7) per 100000 women in 2016, and the most common gynecological cancer has changed from cervical cancer in 1990 to corpus uteri cancer in 2016. Age-standardized incidence rates of ovarian, corpus uteri and vulvovaginal cancers increased from 1.3 (0.5–2.4), 1.7 (0.6–3.0), and 0.3 (0.0–0.7) in 1990 to 4.4 (3.6–5.2), 9.9 (6.8–13.4), and 0.6 (0.2–1.0) in 2016, respectively, showing a 3.3, 5.8 and 1.7-fold increase during this period. Age-standardized incidence rate of cervical cancer was 2.4 (1.7–3.3) cases per 100000 women in 2016 and did not differ significantly from the beginning of the study. An overall reduction was seen in national mortality to incidence ratios (MIR) from 2000 to 2015. Conclusion: The incidence rates of all gynecological cancers in different provinces have shown a converging trend that could indicate that attempts toward health equality have been effective. The declining trend of MIR could be interpreted as advancements in detection of cancer in its early stages and also improvements in treatments, in turn reflecting improvements in access to and quality of care.


2019 ◽  
Vol 26 (4) ◽  
Author(s):  
M. Le ◽  
F. M. Ghazawi ◽  
A. Alakel ◽  
E. Netchiporouk ◽  
E. Rahme ◽  
...  

Background Follicular lymphoma (FL) is the most common indolent lymphoma and the 2nd most common non- Hodgkin lymphoma, accounting for 10%–20% of all lymphomas in the Western world. Epidemiologic and geographic trends of FL in Canada have not been investigated. Our study’s objective was to analyze incidence and mortality rates and the geographic distribution of FL patients in Canada for 1992–2010.Methods Demographic and geographic patient data for FL cases were obtained using the Canadian Cancer Registry, the Registre quebecois du cancer, and the Canadian Vital Statistics database. Incidence and mortality rates and 95% confidence intervals were calculated per year and per geographic area. Rates were plotted using linear regression models to assess trends over time. Overall data were mapped using Microsoft Excel mapping software (Redmond, WA, U.S.A.) to identify case clusters across Canada.Results Approximately 22,625 patients were diagnosed with FL during 1992–2010. The age-standardized incidence rate of this malignancy in Canada was 38.3 cases per million individuals per year. Geographic analysis demonstrated that a number of Maritime provinces and Manitoba had the highest incidence rates, and that the provinces of Nova Scotia and Quebec had the highest mortality rates in the nation. Regional data demonstrated clustering of FL within cities or regions with high herbicide use, primary mining, and a strong manufacturing presence.Conclusions Our study provides a comprehensive overview of the FL burden and its geographic distribution in Canada. Regional clustering of this disease in concentrated industrial zones strongly suggests that multiple environmental factors might play a crucial role in the development of this lymphoma.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5629-5629
Author(s):  
Anirudh Bikmal ◽  
Lakshmi Radhakrishnan ◽  
Ajay K. Nooka

Abstract Background: The trends of incidence of solitary bone plasmacytoma (SBP) varied over time due to the changing definitions and the absence of clarity of the criteria. Prior studies have attempted to identify factors such as older age, gender, race as prognostic factors that influence survival of patients with SBP, but with changing paradigm of myeloma treatments, there is limited literature regarding the incidence, mortality and survival trends of SBP. Methods: We used the SEER registry from 1973-2009 to evaluate the incidence, mortality and survival trends in patients with SBP. The results were reported as crude incidence, mortality and survival rates. Two-sample t-tests, ANOVA as well regression analysis were used to examine correlation. Statistics were computed using the National Cancer Institute SEER*Stat software, version 8.2.0. and SAS software, version 9.4 (SAS Institute Inc, Cary, NC). Using the ICD-O-3 and morphologic codes of 9731/3 to identify cases, the final study cohort consisted of 2,734 cases. Trends were evaluated by the eras of diagnosis: 1973-1980, 1981-1985, 1986-1990, 1991-1995, 1996-2000, 2001-2005, and 2006-2009. Age-adjusted incidence rates (IR), standard mortality rates (SMR), survival rate (SR) were expressed as new cases per 100,000 person-years, and age-adjusted to the 2000 US standard population. Results: The median age of diagnosis of SBP among blacks is 61 years (range, 21-91) compared to others: 60 years (range, 28-88) and whites: 66 years (20-97). The age adjusted incidence rates for black males is: 0.3 (95%CI 0.2, 0.3) followed by black females 0.2 (95%CI 0.1, 0.2) white males 0.2 (95%CI 0.2, 0.2) white females 0.1 (95%CI 0.1, 0.1). The trends in incidence and mortality rates are illustrated in table 1 with highest IR noted for black males during the era 2006-2009. The 5-year survival rates for both males (figure 1) and females (figure 2) seem to be trending down over the eras examined. Regression analysis suggests males and other race have increased odds of survival (HR = 0.829, p=0.0078; HR = 0.54 and p=0.0038, respectively). Conclusions: Similar to myeloma, black patients tend to be diagnosed with SBP younger and have increased incidence. The incidence rates seem to be increasing, highest among blacks males, more likely from increased awareness and diagnosis. The mortality and survival patterns are comparable to whites. Interestingly, while the 5-year survival for myeloma among all racial groups is improving this analysis shows a decreasing trend for SBP. This observation is more likely from including myeloma patients under the diagnosis of SBP over the period of study. Recently, the International Myeloma Working Group (IMWG) clarified the definition of SBP which will help in accurate diagnosis and ultimately can help in accurate representation of the survival trends. Table 1. Incidence and Mortality Rates across Study Eras (SEER-9), 1973-2009 Years White (IR) White (MR) Black (IR) Black (MR) Other (IR) Other (MR) Male 1973-1980 0 0 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.2) 0 (0, 0.1) 1981-1985 0 0 0 (0, 0.2) 0 (0, 0.1) 0 (0, 0.2) 0 (0, 0.1) 1986-1990 0.1 (0.1, 0.2) 0.1 (0, 0.1) 0.1 (0, 0.3) 0.1 (0, 0.2) 0.3 (0.1, 0.5) 0 (0, 0.2) 1991-1995 0.2 (0.1, 0.2) 0.1 (0.1, 0.2) 0.2 (0.1, 0.4) 0 (0, 0.1) 0.1 (0, 0.3) 0.1 (0, 0.2) 1996-2000 0.2 (0.2, 0.3) 0.1 (0.1, 0.1) 0.3 (0.1, 0.5) 0.2 (0.1, 0.4) 0.2 (0.1, 0.4) 0.2 (0, 0.4) 2001-2005 0.4 (0.4, 0.5) 0.2 (0.2, 0.3) 0.5 (0.3, 0.7) 0.3 (0.1, 0.6) 0.2 (0, 0.2) 0 (0, 0.2) 2006-2009 0.4 (0.4, 0.5) 0.2 (0.2, 0.3) 0.7 (0.4, 1) 0.3 (0.1, 0.5) 0.1 (0, 0.2) 0.1 (0, 0.2) Female 1973-1980 0 0 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 1981-1985 0 0 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 0 (0, 0.1) 1986-1990 0.1 (0, 0.1) 0 (0, 0.1) 0.1 (0, 0.2) 0 (0, 0.1) 0 (0, 0.2) 0 (0, 0.2) 1991-1995 0.1 (0.1, 0.1) 0 (0, 0.1) 0.2 (0.1, 0.3) 0.1 (0, 0.2) 0 (0, 0.1) 0 (0, 0.1) 1996-2000 0.1 (0.1, 0.1) 0.1 (0.1, 0.1) 0.1 (0, 0.2) 0.1 (0, 0.2) 0.1 (0.2) 0 (0, 0.1) 2001-2005 0.2 (0.2, 0.2) 0.1 (0.1, 0.2) 0.3 (0.2, 0.4) 0.1 (0, 0.2) 0.1 (0, 0.2) 0 (0, 0.1) 2006-2009 0.2 (0.2, 0.3) 0.1 (0.1, 0.2) 0.3 (0.2, 0.5) 0.2 (0.1, 0.3) 0.1 (0, 0.2) 0 (0, 0.1) Figure 1. 5-year Survival Rates in males (SEER-9), 1973-2012 Figure 1. 5-year Survival Rates in males (SEER-9), 1973-2012 Figure 2. 5-year Survival Rates in females (SEER-9), 1973-2012 Figure 2. 5-year Survival Rates in females (SEER-9), 1973-2012 Disclosures Nooka: Spectrum Pharmaceuticals: Consultancy; Onyx Pharmaceuticals: Consultancy.


2019 ◽  
Vol 70 (8) ◽  
pp. 2879-2882
Author(s):  
Oana Miron ◽  
Adina Magdalena Turcanu ◽  
Bogdan Mihnea Ciuntu ◽  
Vladimir Poroch ◽  
Daniel Timofte

Improvements in early detection of cancer have led to an important decrease in mortality rates of cancer. Given the increased incidence rates and decreased mortality rates, the number of patients surviving cancer is rapidly increasing. Although cancer patients face many physical and psychological symptoms, they also continue to engage in poor health behaviors at rates similar to those of the general-healthy population. The prime example of such unhealthy behavior is smoking. The reports show that smoking rates at the time of diagnosis of cancer vary from 10% to 95%. Our study analyzed how the smoking status influenced the outcome of chemotherapy of 249 patients suffering from various forms of cancer. Our statistical analysis showed that patients who smoked had a significant different response to chemotherapy compared to their nonsmoking peers. This meant that in our sample of 149 cancer suffering patients, individuals who did not smoke had a significant better chance of a partial positive response after chemotherapy compared to patients who smoked regularly. Therefore, tobacco smoking is an adverse prognostic factor associated with a resistance to chemotherapy. These results are important given the fact that cancer patients already face a combination of unpleasant symptoms related to their disease but also from the side effects of their treatment. Uncovering the exact mechanisms through which smoking is affecting the outcome of chemotherapy may help in increasing the quality of life, the symptom burden or the final outcome of chemotherapy.


2021 ◽  
Vol 319 ◽  
pp. 01071
Author(s):  
Faiçal El Hattimy ◽  
Chafiq Fouad ◽  
Hermann-Désiré Lallié ◽  
Abdelrhani Mokhtari ◽  
Abdelmajid Soulaymani ◽  
...  

Snakebites are a real public health problem in Morocco, from the point of view of incidence and mortality. Inorder to contribute to the reduction of the resulting morbidity and mortality, the present work aims to describe the epidemiological profile of cases of Snakebites and to follow the spatio-temporal trends of the health indicators studied (incidence, fatality and mortality). The methodology adopted consists of a retrospective analysis of the cases collected from the Anti Poison and Pharmacovigilance Center of Morocco from specific hospitalization records. Between 2012 and 2015, the MPCC gathered 224 cases. The mean age was 26.9 ± 18.9 years with a sex ratio (M / F) of 1.4. Most of the bites occurred during hot seasons (84%) and in rural areas (95%). The time to hospitalization exceeded 24 hours in 7% of cases. Clinically, compartment syndrome was observed in 17 patients, renal failure in 13 patients and shock in 13 patients. The distribution according to clinical gradation was almost uniform. From a therapeutic standpoint, in addition to the antivenom, two types of treatment were the most recommended: symptomatic treatment based on the administration of analgesics (n = 168) and on the administration of an antitetanus serum (n = 99), and treatment involving transfusion (n = 58). Analysis of all of these files enabled us to detect parameters having a direct impact on morbidity and mortality following a bite and ophidian envenomation, on which the competent authorities should focus in order to thwart this scourge and its complications.


2021 ◽  
Vol 20 (4) ◽  
pp. 30-38
Author(s):  
A. A. Mordovskii ◽  
A. A. Aksarin ◽  
A. M. Parsadanyan ◽  
M. D. Ter-Ovanesov ◽  
P. P. Troyan

The aim of the study was to assess the lung cancer incidence and mortality in the Khanty-mansi autonomous okrug – Yugra during the period 1999–2019.Material and methods. We have studied the lung cancer incidence and mortality rates in Yugra over the last 21 years (1999–2019).Results. In Yugra, the lung cancer (lc) incidence rates increased by 24.7 % from 1999 to 2019, demonstrating higher rates than those in the Russian Federation (RF), where lc incidence rates decreased by 20.3 %. In 2019, the age-standardized incidence rate was 30.5 per 100,000 (22.7 for RF); the age-standardized mortality rate was 16.4 per 100,000 (18.4 for RF). The mortality rate from lc in Yugra was 9.6 times higher in males than in females (35.5 vs. 3.7 per 100,000). The cross-correlation analysis revealed a correlation between the lc incidence/mortality and air pollution in Yugra. The main carcinogens in Yugra were formaldehyde, phenol, nitrogen dioxide, and benzapyrene. The assessment of the relationship between the age-standardized lc incidence/mortality rates and the amount of pollutants emitted into the atmosphere revealed that their synergistic effects with tobacco smoking can double the risk of lung cancer development. The increase in the number of chest computed tomography (ct) scans performed in the context of the pandemic caused by covid-19 infection led to an 18 % increase in the number of incidentally detected pulmonary nodules, of which 9 % of cases were diagnosed as lc.Conclusion. The lc incidence rates in Yugra tended to increase. The high rate of lc incidence is caused by man-made and natural factors, which requires the implementation of a screening program with the use of low-dose computed tomography in order to improve the early detection and prevention of this disease.


Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3421
Author(s):  
Daniël J. van der Meer ◽  
Henrike E. Karim-Kos ◽  
Marianne van der Mark ◽  
Katja K. H. Aben ◽  
Rhodé M. Bijlsma ◽  
...  

Adolescent and young adult (AYA) cancer patients, aged 15–39 years at primary cancer diagnosis, form a distinct, understudied, and underserved group in cancer care. This study aimed to assess long-term trends in incidence, survival, and mortality of AYA cancer patients within the Netherlands. Data on all malignant AYA tumours diagnosed between 1990–2016 (n = 95,228) were obtained from the Netherlands Cancer Registry. European age-standardised incidence and mortality rates with average annual percentage change (AAPC) statistics and five-year relative survival rates were calculated. The overall cancer incidence increased from 54.6 to 70.3 per 100,000 person-years (AAPC: +1.37%) between 1990–2016, and increased for both sexes individually and for most cancer types. Five-year relative survival overall improved from 73.7% in 1990–1999 to 86.4% in 2010–2016 and improved for both sexes and most cancer types. Survival remained poor (<60%) for rhabdomyosarcoma, lung, stomach, liver, bladder, and pancreatic carcinomas, among others. Mortality rates among male AYAs overall declined from 10.8 to 6.6 (AAPC: −1.64%) and from 14.4 to 10.1 per 100,000 person-years (AAPC: −1.81%) for female AYAs since 1990. Mortality rates remained unchanged for male AYAs aged 20–24 and 25–29 years. In conclusion, over the past three decades, there has been a considerable increase in cancer incidence among AYAs in the Netherlands. Meanwhile, the survival improved and the mortality overall declined. Survival at five-years now well exceeds above 80%, but did not do so for all cancer types.


2018 ◽  
pp. 1-11 ◽  
Author(s):  
Christian S. Alvarez ◽  
Shama Virani ◽  
Rafael Meza ◽  
Laura S. Rozek ◽  
Hutcha Sriplung ◽  
...  

Purpose Prostate cancer is the second most common malignancy among men worldwide, and it poses a significant public health burden that has traditionally been limited mostly to developed countries. However, the burden of the disease is expected to increase, affecting developing countries, including Thailand. We undertook an analysis to investigate current and future trends of prostate cancer in the province of Songkhla, Thailand, using data from the Songkhla Cancer Registry from 1990 to 2013. Methods Joinpoint regression analysis was used to examine trends in age-adjusted incidence and mortality rates of prostate cancer and provide estimated annual percent change (EAPC) with 95% CIs. Age-period-cohort (APC) models were used to assess the effect of age, calendar year, and birth cohort on incidence and mortality rates. Three different methods (Joinpoint, Nordpred, and APC) were used to project trends from 2013 to 2030. Results Eight hundred fifty-five cases of prostate cancer were diagnosed from 1990 to 2013 in Songkhla, Thailand. The incidence rates of prostate cancer significantly increased since 1990 at an EAPC of 4.8% (95% CI, 3.6% to 5.9%). Similarly, mortality rates increased at an EAPC of 5.3% (95% CI, 3.4% to 7.2%). The APC models suggest that birth cohort is the most important factor driving the increased incidence and mortality rates of prostate cancer. Future incidence and mortality of prostate cancer are projected to continue to increase, doubling the rates observed in 2013 by 2030. Conclusion It is critical to allocate resources to provide care for the men who will be affected by this increase in prostate cancer incidence in Songkhla, Thailand, and to design context-appropriate interventions to prevent its increasing burden.


2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 10569-10569
Author(s):  
Dorothy Yang ◽  
Chinmay Jani ◽  
Conor Crowley ◽  
Richard Goodall ◽  
Joseph Shalhoub ◽  
...  

10569 Background: Epidemiological data relating to non-melanoma skin cancer (NMSC), including squamous cell carcinoma (SCC), is highly under-reported and under-studied due to its lower metastatic potential. In recent years, incidence and prevalence of SCC has increased in many countries due to earlier detection, increased ultraviolet light exposure, as well as increasing life expectancy. This investigation compared trends in SCC incidence, mortality and disability-adjusted life years (DALYs) in 33 countries. Methods: We utilized the Global Burden of Disease (GBD) database for 33 countries, including the European Union nations as well as other selected high-income countries including the UK and USA. We extracted data including age-standardized incidence rates (ASIRs), age-standardized mortality rates (ASMRs) and DALYs for SCC of the skin from 1990 to 2017. Joinpoint regression analysis was used to describe the trends. Results: For both sexes, the highest ASIRs were seen in the USA and Australia: ASIRs were 362.8/100,000 and 283.7/100,000 respectively for males, and 171.2/100,000 and 152.4/100,000 respectively for females. Males had higher ASIRs than females at the end of the observation period in all countries. In contrast, the highest ASMRs for males were observed in Australia (2.77/100,000) and Latvia (2.44/100,000), while the highest ASMRs for females were observed in Romania (0.95/100,000) and Croatia (0.90/100,000). The highest DALYs for both sexes were seen in Australia and Romania: DALYs were 58.4/100,000 and 43.8/100,000 respectively for males, and 16.9/100,000 and 14.9/100,000 respectively for females. Over the observation period, there were more countries demonstrating decreasing trends in mortality than in incidence. There was also a disparity between which countries had comparatively high mortality rates and which had high incidence rates – for instance, the USA, which had by far the highest SCC incidence rates, had among the lower mortality rates. Overall reductions in DALYs were observed in 24 of 33 countries for males, and 25 countries for females. Conclusions: Over the past 27 years, although trends in SCC incidence have risen in most countries, there is evidence that mortality rates have been decreasing, especially towards the end of the observation period. Overall, burden of disease as assessed using DALYs has decreased in the majority of countries. Future work will explore potential explanatory factors for the observed disparity in trends in SCC incidence and mortality.


Sign in / Sign up

Export Citation Format

Share Document